Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

DIY tirzepatide, internet detective work and insurance appeals: The lengths 3 people are going to for weight loss drugs. Story by Natalie Rahhal • 1w.

In this second half of a recent interview on trends in tirzepatide use, Jaime Almandoz, MD, MBA, calls for scalable, team-based care models to support the growing use of obesity medications like ...

The researchers reported that tirzepatide (0% to 40.6%) and semaglutide 2.4 mg (0% to 32.2%) increased significantly among adults without diabetes with any or incident use of WLMs, though ...

The active ingredient in the drug, tirzepatide, has already been approved for the treatment of Type 2 diabetes under the name Mounjaro since May 2022. But the FDA's new approval means adults who ...

DIY tirzepatide, internet detective work and insurance appeals: The lengths 3 people are going to for weight loss drugs "Not being on it is not an option." Natalie Rahhal, Reporter.